Fordonal, S.a.

Anphar, S.a.

Walton S.a.

Robert G Spickett

Jacinto M Mauri

Armando Vega-Noverola

Jose M Soto

Fernando P Noguera

Jesus E Puchades

Armando V Noverola

Jose P Soto

Jacinto Moragues-Mauri

Juan C Escoi

Jose L Vidal

Jose Boix-Igleasias

Jose M Prieto-Soto

Fernando Pujol-Noguera

Antacid powders, tablets etc. of prolonged gastric residence time have an internal phase of a solid antacid and excipient surrounded by a solid external phase containing a hydrophobic substance e.g. an ester of glycerol with palmitic or stearic acid, a hydroxylated polyalkene and a non-ionic emulsifier.

Antacid compositions with prolonged gastric residence time

A method of treating anxiety including administering to a person to be treated an effective amount of compounds of the general formula: ##STR1## wherein the various substituents are defined hereinbelow have pharmacological properties rendering them useful as antiemetic agents with reduced undesirable side-effects or as anxiolytic agents. Various methods are described for their preparation involving formation of the amide link, etherification of the 2-hydroxy derivative, introducing the R.sup.5 CH.sub.2 group on the N-unsubstituted azabicyclooctane or nonane or, for 4-amino compounds, by hydrolysing a 4-acylamino derivative.

Anxiolytic N-substituted benzamides

Compounds of the general formula: ##STR1## wherein the various substituents are defined hereinbelow have pharmacological properties rendering them useful as antiemetic agents with reduced undesirable side-effects. Various methods are described for their preparation involving formation of the amide link, etherification of the 2-hydroxy derivative, introducing the R.sup.5 CH.sub.2 group on the N-unsubstituted azabicyclooctane or nonane or, for 4-amino compounds by hydrolysing a 4-acylamino derivative.

Antiemetic N-substituted benzamides

Substituted benzamides of the general formula I ##STR1## in which: R represents an alkoxy, alkenyloxy or alkynyloxy group containing up to 7 carbon atoms in the group,

Benzamides

A process for producing basic aluminum magnesium carbonate, Al.sub.2 Mg.sub.6 (OH).sub.14 (CO.sub.3).sub.2.4H.sub.2 O, by carbonating an aluminum hydroxide (Al(OH).sub.3) and magnesium hydroxide aqueous reaction mixture with carbon dioxide in the presence of at least 6 moles of a base selected from the group consisting of ammonia, mono, di or trialkylamines, pyridine or piperidine, per mole of Al.sub.2 O.sub.3 present. The product is useful as an antacid.

Basic aluminum magnesium carbonate

Compounds of the general formula I: ##STR1## wherein R.sup.1 represents a thienyl group, or a phenyl group optionally substituted by a halogen (preferably fluorine or chlorine) atom, a lower alkoxy or lower alkyl group, R.sup.2 represents a hydrogen or halogen (preferably fluorine) atom, a lower alkoxy or lower alkyl group, R.sup.3 represents a hydrogen or halogen (preferably fluorine) atom, a lower alkylthio, lower alkoxy or lower alkyl group, or a cycloalkyl group containing 5 or 6 carbon atoms, or a group of the general formula: ##STR2## wherein R.sup.4 and R.sup.5 singly each represents a hydrogen atom or lower alkyl group, R.sup.6 represents a cycloalkyl, hydroxymethyl, carboxy or lower alkoxycarbonyl group, and W represents a carbonyl ##STR3## or a hydroxymethylene [viz. --CH(OH)--] group, and pharmacologically acceptable salts thereof possess potent selective Histamine H.sub.1 -receptor blocking and calcium antagonist properties and are of interest in the treatment of a variety of respiratory, allergenic and cardiovascular disease states. The new compounds can be prepared by various methods based on the condensation of .alpha.-substituted benzyl halides with N-(benzoylpropyl or phenyl-hydroxypropyl)-4-hydroxy piperidines or condensation of di-substituted-methoxy-piperidines with a benzoylpropyl halide or a phenyl-hydroxypropyl-halide followed, where necessary, by removal of protecting groups.

Piperidine derivatives

A new basic aluminium magnesium carbonate of the formula Al.sub.2 Mg.sub.6 (OH).sub.14 (CO.sub.3).sub.2.4H.sub.2 O has been found to be useful in pharmaceutical formulations for the treatment of upper gastrointestinal tract disturbances associated with excess acid and pepsin secretion or biliary reflux.

Basic aluminium magnesium carbonate

This invention relates to new therapeutically useful piperidine derivatives and salts thereof. The invention also relates to processes for their preparation and pharmaceutical compositions containing them.

This invention relates to piperidine derivatives. More particularly, the invention relates to substituted benzoic acid amides of N-substituted piperidine and to pharmaceutical compositions thereof, which are useful in antagonizing the effects of dopamine or dopaminergic agents of endogenous or exogenous origin and in treating nausea and vomiting resulting from gastrointestinal disorders, congestive heart failure, post operative conditions, etc., other gastrointestinal disorders such as dyspepsia, flatulence, bile regurgitations, hiatus hernia, peptic ulcer, reflux aerophagitis, gastritis, duodenitis, and cholethiasis, and a variety of conditions affecting the central nervous system such as acute and chronic psychoses, maniacal psychosis, schizophrenias, serious disturbances of behavior and non-melancholic depressive state and migraine. The invention also relates to methods of preparing piperidine derivatives.

Growing community of inventors

Barcelona, Spain

Robert G Spickett